Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

By R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli. New England Journal of Medicine, 2007

762 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Neurology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/41f7e51e58b8b06fa9d4e6fb37fd6b67bc21c525

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Victor M. Montori

Citations in the corpus

• Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. (2011, background): “Patients with Parkinson’s disease receiving at least 3 mg of cabergoline daily are at risk for moderate to severe cardiac valve regurgitation (96, 97).”
• Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. (2008, background): “However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”